In 2013, NIAID launched the Antibacterial Resistance Leadership Group (ARLG), a major clinical effort to address antibacterial resistance (AR). Studies conducted by the ARLG include clinical testing of new drugs to treat multidrug-resistant Gram-negative bacteria, evaluating diagnostic devices in clinical settings, evaluating the effectiveness of new antibacterial stewardship programs, and optimizing treatment regimens to reduce the emergence of resistance. The ARLG is also committed to mentoring the next generation of clinical scientists in the field of AR. In addition, the ARLG is available to consult with industry and provide advice, guidance, and protocol design for drug, device, or diagnostic development.
Main Areas of Focus
Since its inception, the group has focused on four key areas:
- Infections caused by Gram-negative bacteria, such as Escherichia coli, Klebsiella pneumoniae and other carbapenem-resistant Enterobacteriaceae (CRE)
- Infections caused by Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci
- Antimicrobial stewardship and infection prevention
The ARLG is led by two Principal Investigators, Dr. Vance Fowler, Duke University, and Dr. Henry Chambers, UCSF. Work is supported by ARLG’s expert committees and the Duke Clinical Research Institute (DCRI). NIAID/Division of Microbiology and Infectious Diseases (DMID) provides oversight and direction for the ARLG.